Want to join the conversation?
$GILD 2Q15 Call: 83% of genotype 1 patients have direct access to Harvoni, a percentage that has remained stable since 1Q15. In Europe, hepatitis C revenue was more than $1.1Bil, with over 30,000 estimated new patient starts. Saw particularly high patient initiations in Spain, Italy and Portugal during the quarter.
$EXTR has been on an interesting uptrend, fundamentals kinda tricky but solid technical. Earnings 5th
Wow! $MCD scores again.